[Improvement of malnutrition indices in adult patients with end stage renal disease by recombinant human growth hormone].
Recombinant human growth hormone (r-hGH), 1 U/kg body weight/week, was administered subcutaneously for 2-4 weeks to two end stage renal disease patients with severe malnutrition. Following r-hGH, there were significant increase in hematocrit level and serum concentration of albumin, IGF-1 and GH, and decrease of urea nitrogen. It was concluded that r-hGH exerts a therapeutic effect to nutritional status in renal failure patients by improving severe hypoalbuminemia, susceptibility to infectious disease, intractable ascites and so on.
Sanaka
T
T
Department of Medicine, Kidney Center, Tokyo Women's Medical College.
Sugino
N
N
D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008875:Middle Aged; D009748:Nutrition Disorders / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects
D011994:Recombinant Proteins; D013006:Growth Hormone